drug

VALBENAZINE TOSYLATE

Marketedupdated 3mo ago

by $NBIX NEUROCRINE BIOSCIENCES INC

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for movement disorder and 1 investigational indication.

all catalysts(4)

approval · 4

INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — FDA approval

VALBENAZINE TOSYLATE — FDA approval

VALBENAZINE TOSYLATE — FDA approval

INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — FDA approval

VALBENAZINE TOSYLATE

→

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 8, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (132)

Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-3046)US 10874648
Oct 10, 2037method-of-use (U-3055)US 10874648
Oct 10, 2037method-of-use (U-3046)US 10874648
Oct 10, 2037method-of-use (U-3055)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-3055)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-3076)US 10912771
Oct 10, 2037method-of-use (U-3076)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Nov 8, 2027method-of-use (U-3055)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-3055)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y

FDA exclusivities (9)

Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

VALBENAZINE TOSYLATE

Marketedupdated 3mo ago

by $NBIX NEUROCRINE BIOSCIENCES INC

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for movement disorder and 1 investigational indication.

all catalysts(4)

approval · 4

INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — FDA approval

VALBENAZINE TOSYLATE — FDA approval

VALBENAZINE TOSYLATE — FDA approval

INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — FDA approval

VALBENAZINE TOSYLATE

→

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 8, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (132)

Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 10, 2040method-of-use (U-1995)US 10940141
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Aug 14, 2039method-of-use (U-1995)US 11026931
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Nov 14, 2038method-of-use (U-3055)US 11654142
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11026939
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Sep 18, 2038formulationUS 11311532
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857137
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-1995)US 10857148
Oct 10, 2037method-of-use (U-3046)US 10874648
Oct 10, 2037method-of-use (U-3055)US 10874648
Oct 10, 2037method-of-use (U-3046)US 10874648
Oct 10, 2037method-of-use (U-3055)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10874648
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-3055)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-3076)US 10912771
Oct 10, 2037method-of-use (U-3076)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10912771
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10952997
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 10993941
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-1995)US 11040029
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Oct 10, 2037method-of-use (U-3055)US 11439629
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906902
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10906903
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Dec 22, 2036compositionUS 10919892
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10065952
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10844058
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851103
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Oct 28, 2036compositionUS 10851104
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Apr 11, 2031compositionUS 80396274.6y
Nov 8, 2027method-of-use (U-3055)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-3055)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y
Nov 8, 2027method-of-use (U-1995)US 83576971.2y

FDA exclusivities (9)

Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2030ODE-440Orphan Drug (7y)4.0y
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)
Aug 18, 2026I-925Indication (3y)

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

VALBENAZINE TOSYLATE

🐶 often sniffed alongside

all catalysts(4)

Patent cliff

patents (132)

FDA exclusivities (9)

News(0)

Report a data issue

comments(0)

VALBENAZINE TOSYLATE

🐶 often sniffed alongside

all catalysts(4)

Patent cliff

patents (132)

FDA exclusivities (9)

News(0)

Report a data issue

comments(0)